Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcadia Biosciences (RKDA) EPS (Weighted Average and Diluted) (2020 - 2025)

Arcadia Biosciences filings provide 6 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.98 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 67.22% to -$0.98 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.72, a 66.73% increase, with the full-year FY2025 number at -$1.71, up 66.92% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.98 in Q4 2025 for Arcadia Biosciences, down from $0.62 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.9 in Q1 2025 to a low of -$27.3 in Q4 2021.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$1.08 (2024), compared with a mean of -$3.22.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 7454.55% in 2022 and later surged 206.74% in 2025.
  • Arcadia Biosciences' EPS (Weighted Average and Diluted) stood at -$27.3 in 2021, then surged by 106.23% to $1.7 in 2022, then plummeted by 112.94% to -$0.22 in 2023, then crashed by 1259.09% to -$2.99 in 2024, then surged by 67.22% to -$0.98 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.98 (Q4 2025), $0.62 (Q3 2025), and -$3.26 (Q2 2025) per Business Quant data.